Law Journal Newsletters

An ALM Website

MEDICAL MALPRACTICE LAW & STRATEGY

January 2013

Drug Marketing to Doctors: Changes May Be On the Way

By Janice G. Inman

The cornerstone of many FDA enforcement actions against pharmaceuticals manufacturers in recent years has been the charge that they have "misbranded" their pharmaceutical products by promoting them for uses not approved by the FDA. Now, the Second Circuit has thrown the concept of criminal liability for misbranding by means of off-label-use promotion into turmoil.

Log In

Subscribers: Log in below to read the full story

Already subscribe but haven't registered for all the benefits of the website?

Subscribe

Click below to subscribe to
MEDICAL MALPRACTICE LAW & STRATEGY

Subscribe

Pay-Per-View

You can purchase this article for $20.00
Click below

Purchase Article

ARTICLES FROM RELATED NEWSLETTERS

ACCOUNTING and FINANCIAL PLANNING for LAW FIRMS

The Panama Papers: A Small Part of a Larger Challenge?

The Panama Papers has become a new buzz phrase. Information contained in the Panama Papers — the unprecedented leak of 11.5 million internal documents from the Panamanian law firm Mossack Fonseca — illustrates the dangers of noncompliance for U.S. taxpayers and for citizens of other countries with whom the U.S. has exchange of information agreements.

CYBERSECURITY LAW & STRATEGY

Navigating New Terrain: Law Firms Facing Unprecedented Cyber Risk

For years, various government authorities and security experts warned the legal industry about the proverbial cyber target painted on their chest. Given nebulous reporting legislations, the data breaches at law firms remained below the press horizon. But you can only dodge so many bullets until one hits the industry square in the chest.